S&P 500 could hit 8,000 in 2026 on more easing from Fed: JPMorgan
10X Genomics Inc (TXG) stock reached a 52-week high, touching 17.7 USD. This milestone reflects a significant upward trend for the company, which has experienced a 23.85% increase in its stock price over the past year. Even more impressive is the stock’s remarkable 97.84% surge over the past six months. According to InvestingPro data, the company maintains a "GOOD" overall financial health score of 3.0, despite not being profitable over the last twelve months. The rise in stock value underscores investor confidence and suggests positive market sentiment surrounding the company’s recent performance and future prospects. With a high beta of 2.19, InvestingPro tips indicate that TXG stock price movements are quite volatile. As 10X Genomics continues to innovate in the field of genomics, its stock’s upward trajectory signals strong potential for continued growth and resilience in a competitive industry. The company’s current trading price is very close to its Fair Value, based on InvestingPro analysis. Discover 7 more ProTips and access the comprehensive Pro Research Report available for this genomics innovator.
In other recent news, 10x Genomics reported a significant earnings surprise for the second quarter of 2025, posting an earnings per share (EPS) of $0.28, surpassing the forecast of -$0.37. The company’s revenue for the quarter also exceeded expectations, reaching $173 million, a 24.03% increase over projections. In another development, 10x Genomics launched an updated version of its Chromium Flex assay, which now features plate-based multiplexing, allowing researchers to analyze up to 384 samples and 100 million cells per week. This new version aims to enhance scalability for large-scale research projects.
Additionally, 10x Genomics announced a partnership with AI company Anthropic to integrate its analysis tools into Anthropic’s Claude for Life Sciences platform. This collaboration is designed to make complex biological analysis more accessible through natural language conversations. Piper Sandler recently initiated coverage of 10x Genomics with a Neutral rating, highlighting the company’s leading position in the single-cell market. These developments reflect 10x Genomics’ ongoing efforts to expand its technological capabilities and market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.